Tenofovir exalidex

Drug Profile

Tenofovir exalidex

Alternative Names: CMX 157; HDP-Tenofovir; Hexadecyloxypropyl-tenofovir; TXL

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Chimerix
  • Developer Chimerix; ContraVir Pharmaceuticals
  • Class Antiretrovirals; Phosphonic acids; Purines; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B
  • Suspended HIV infections

Most Recent Events

  • 13 Oct 2016 Positive interim efficacy,safety and pharmacokinetic data from a phase Ib/IIa trial in hepatitis B released by ContraVir Pharmaceuticals
  • 12 Sep 2016 New pharmacodynamics data from preclinical study presented at The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016) and The International Liver Congress™ 2016 (ILC-2016)
  • 01 Sep 2016 ContraVir completes a phase I pharmacokinetic trial in Healthy volunteers in Thailand (NCT02585440)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top